◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › CTNM

Contineum Therapeutics, Inc. (CTNM) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-16

Contineum Therapeutics, Inc. (CTNM) operates in the Biotechnology industry and is headquartered in San Diego, United States with about 51 employees. Its market capitalization is roughly $547 million. In the fiscal year ended 2025-12-31, CTNM reported $0M in revenue and ($60M) in net income.

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States.

Interactive charts & full statements →

CTNM Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$0M$0M$50M$0M
Operating Income (EBIT)($68M)($51M)$16M($23M)
Net Income($60M)($42M)$23M($24M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CTNM Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($17M)($17M)($15M)($18M)($18M)
Net Income($14M)($15M)($13M)($16M)($16M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CTNM Free Cash Flow History

CTNM Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$277M$213M$130M$51M
Total Liabilities$16M$15M$198M$144M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CTNM viewer.

Other Companies in Biotechnology

← CTMXAll stocksCTNT →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.